PE20231108A1 - Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica - Google Patents
Moduladores del regulador de la conductancia transmembrana de la fibrosis quisticaInfo
- Publication number
- PE20231108A1 PE20231108A1 PE2023001370A PE2023001370A PE20231108A1 PE 20231108 A1 PE20231108 A1 PE 20231108A1 PE 2023001370 A PE2023001370 A PE 2023001370A PE 2023001370 A PE2023001370 A PE 2023001370A PE 20231108 A1 PE20231108 A1 PE 20231108A1
- Authority
- PE
- Peru
- Prior art keywords
- cystic fibrosis
- modulators
- transmembrane conductance
- regulator
- methyl
- Prior art date
Links
- 201000003883 Cystic fibrosis Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Amplifiers (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A COMPUESTOS MACROCICLICOS DE FORMULA (I) DONDE LOS ANILLOS A Y B, R3, R4, R5, W1, W2, L1, L2, Z Y RYN SON TAL COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO. SON COMPUESTOS PREFERIDOS: (11R)-11-(CICLOPENTILMETIL)-6-(2,6-DIMETILFENIL)-12-[(6-ISOPROPIL-5-METIL-PIRROLO[2,3-B]PIRAZIN-3-IL)METIL]-2,2-DIOXO-9-OXA-2 lamda 6-TIA-3,5,12,19-TETRAZATRICICLO[12.3.1.14,8]NONADECA-1(18),4(19),5,7,14,16-HEXAEN-13-ONA; 11-(3,3-DIMETILCICLOBUTIL)-6-(2,6-DIMETILFENIL)-12-[[6-[(2R)-2-METILPIRROLIDIN-1-IL]PIRAZIN-2-IL]METIL]-2,2-DIOXO-9-OXA-2 lamda 6-TIA-3,5,12,19-TETRAZATRICICLO[12.3.1.14,8]NONADECA-1(18),4(19),5,7,14,16-HEXAEN-13-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUISTICA (CFTR) SIENDO UTILES EN EL TRATAMIENTO DE FIBROSIS QUISTICA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063088686P | 2020-10-07 | 2020-10-07 | |
PCT/US2021/053858 WO2022076622A2 (en) | 2020-10-07 | 2021-10-06 | Modulators of cystic fibrosis transmembrane conductance regulator |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20231108A1 true PE20231108A1 (es) | 2023-07-19 |
Family
ID=80091350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001370A PE20231108A1 (es) | 2020-10-07 | 2021-10-06 | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica |
Country Status (19)
Country | Link |
---|---|
US (1) | US20240150377A1 (es) |
EP (1) | EP4225765A2 (es) |
JP (1) | JP2023545080A (es) |
KR (1) | KR20230107725A (es) |
CN (1) | CN116601158A (es) |
AR (1) | AR123708A1 (es) |
AU (1) | AU2021358512A1 (es) |
CA (1) | CA3197683A1 (es) |
CL (1) | CL2023000988A1 (es) |
CO (1) | CO2023005006A2 (es) |
CR (1) | CR20230198A (es) |
DO (1) | DOP2023000067A (es) |
EC (2) | ECSP23033092A (es) |
IL (1) | IL301757A (es) |
MX (1) | MX2023004072A (es) |
PE (1) | PE20231108A1 (es) |
TW (1) | TW202229298A (es) |
UY (1) | UY39457A (es) |
WO (1) | WO2022076622A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022544383A (ja) | 2019-08-14 | 2022-10-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrモジュレータの結晶形態 |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
IL303519A (en) | 2020-12-10 | 2023-08-01 | Vertex Pharma | Methods of treatment for cystic fibrosis |
EP4472635A1 (en) | 2022-02-03 | 2024-12-11 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AU2023215372A1 (en) | 2022-02-03 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
CR20240457A (es) * | 2022-04-06 | 2024-12-11 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
JP2025517322A (ja) | 2022-05-16 | 2025-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症の治療方法 |
WO2024054845A1 (en) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocycic compounds, compositions, and methods of using thereof |
IL319374A (en) * | 2022-09-07 | 2025-05-01 | Sionna Therapeutics Inc | Macrocyclic compounds, compositions and methods of using them |
WO2024056779A1 (en) * | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide |
CN116143722B (zh) * | 2023-03-09 | 2024-05-31 | 南京师范大学 | 一种次磺酰胺类化合物的合成工艺 |
WO2025076240A1 (en) * | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cystic fibrosis transmembrane conductance regulator |
WO2025129104A1 (en) * | 2023-12-15 | 2025-06-19 | Sionna Therapeutics Inc. | Compounds, compositions, and methods of using thereof |
CN119191996A (zh) * | 2024-11-28 | 2024-12-27 | 浙江省质量科学研究院 | 一种双羟乙基氨基丙基羟乙基油胺的合成方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
EP2489659B1 (en) | 2004-06-24 | 2017-12-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
HUE032640T2 (en) | 2005-11-08 | 2017-10-30 | Vertex Pharma | Heterocyclic modulator of ATP-binding cassette transcripts |
RS60205B1 (sr) | 2005-12-28 | 2020-06-30 | Vertex Pharma | Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
WO2007134279A2 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
MX364936B (es) | 2007-12-07 | 2019-05-15 | Vertex Pharma | Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos. |
ES2611077T3 (es) | 2007-12-07 | 2017-05-04 | Vertex Pharmaceuticals Incorporated | Forma solida de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamida)-3-metilpiridin-2-il) benzoico |
JP5575768B2 (ja) | 2008-08-13 | 2014-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | 薬学的組成物およびその投与 |
KR20110063578A (ko) | 2008-09-29 | 2011-06-10 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 투여 단위 |
KR101587389B1 (ko) | 2008-11-06 | 2016-01-28 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송자의 조절자 |
PT2408750E (pt) | 2009-03-20 | 2015-10-15 | Vertex Pharma | Processo para a produção de modeladores do regulador de condutância transmembranar da fibrose cística |
DK2826776T3 (da) | 2010-03-25 | 2020-12-14 | Vertex Pharma | Fast dispersion af amorf form af (r)-1(2,2-difluorbenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluor-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropancarboxamid |
EP2556009B1 (en) | 2010-04-09 | 2016-02-10 | Ekso Bionics | Exoskeleton load handling system and method of use |
SG184987A1 (en) | 2010-04-22 | 2012-11-29 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
NZ603042A (en) | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
BR112013004130A2 (pt) | 2010-08-27 | 2016-07-05 | Vertex Pharma | composição farmacêutica e administrações da mesma |
SMT201700302T1 (it) | 2011-05-18 | 2017-07-18 | Concert Pharmaceuticals Inc | Derivati deuterati di ivacaftor |
HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
US20130224293A1 (en) | 2012-02-27 | 2013-08-29 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
WO2014014841A1 (en) | 2012-07-16 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
JP6302923B2 (ja) | 2012-11-02 | 2018-03-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Cftrが媒介する疾患の処置のための医薬組成物 |
WO2014078842A1 (en) | 2012-11-19 | 2014-05-22 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
PL3131582T3 (pl) | 2014-04-15 | 2018-10-31 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
UA125245C2 (uk) * | 2014-10-06 | 2022-02-09 | Вертекс Фармасьютикалз Інкорпорейтед | Модулятори регулятора трансмембранної провідності при муковісцидозі |
UA124619C2 (uk) | 2015-09-21 | 2021-10-20 | Вертекс Фармасьютікалз (Юроп) Лімітед | Введення дейтерованих підсилювачів cftr |
AU2017352206B2 (en) | 2016-10-27 | 2022-03-03 | Vertex Pharmaceuticals (Europe) Limited | Methods of treatment with deuterated CFTR potentiators |
WO2019156946A2 (en) * | 2018-02-06 | 2019-08-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for improving cftr function in cystic fibrosis-affected cells |
MX2020008268A (es) * | 2018-02-15 | 2020-09-21 | Vertex Pharma | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos. |
US20220071971A1 (en) * | 2018-12-21 | 2022-03-10 | Novartis Ag | Macrocyclic compounds and their use in the treatment of disease |
UY38630A (es) * | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
IL301755A (en) * | 2020-10-07 | 2023-05-01 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
-
2021
- 2021-10-06 AU AU2021358512A patent/AU2021358512A1/en active Pending
- 2021-10-06 KR KR1020237015292A patent/KR20230107725A/ko active Pending
- 2021-10-06 IL IL301757A patent/IL301757A/en unknown
- 2021-10-06 JP JP2023521520A patent/JP2023545080A/ja active Pending
- 2021-10-06 CN CN202180082021.0A patent/CN116601158A/zh active Pending
- 2021-10-06 US US18/248,071 patent/US20240150377A1/en active Pending
- 2021-10-06 EP EP21830544.9A patent/EP4225765A2/en active Pending
- 2021-10-06 CR CR20230198A patent/CR20230198A/es unknown
- 2021-10-06 PE PE2023001370A patent/PE20231108A1/es unknown
- 2021-10-06 CA CA3197683A patent/CA3197683A1/en active Pending
- 2021-10-06 WO PCT/US2021/053858 patent/WO2022076622A2/en active Application Filing
- 2021-10-06 MX MX2023004072A patent/MX2023004072A/es unknown
- 2021-10-07 TW TW110137345A patent/TW202229298A/zh unknown
- 2021-10-07 UY UY0001039457A patent/UY39457A/es unknown
- 2021-10-07 AR ARP210102778A patent/AR123708A1/es unknown
-
2023
- 2023-04-05 CL CL2023000988A patent/CL2023000988A1/es unknown
- 2023-04-05 DO DO2023000067A patent/DOP2023000067A/es unknown
- 2023-04-20 CO CONC2023/0005006A patent/CO2023005006A2/es unknown
- 2023-05-04 EC ECSENADI202333092A patent/ECSP23033092A/es unknown
- 2023-05-04 EC ECSENADI202332843A patent/ECSP23032843A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4225765A2 (en) | 2023-08-16 |
CO2023005006A2 (es) | 2023-09-08 |
CL2023000988A1 (es) | 2023-09-15 |
ECSP23033092A (es) | 2023-06-30 |
CA3197683A1 (en) | 2022-04-14 |
AU2021358512A9 (en) | 2024-10-24 |
TW202229298A (zh) | 2022-08-01 |
MX2023004072A (es) | 2023-07-05 |
CN116601158A (zh) | 2023-08-15 |
ECSP23032843A (es) | 2023-06-30 |
AU2021358512A1 (en) | 2023-05-18 |
UY39457A (es) | 2022-05-31 |
CR20230198A (es) | 2023-07-03 |
KR20230107725A (ko) | 2023-07-17 |
JP2023545080A (ja) | 2023-10-26 |
WO2022076622A2 (en) | 2022-04-14 |
AU2021358512A8 (en) | 2023-05-25 |
IL301757A (en) | 2023-05-01 |
AR123708A1 (es) | 2023-01-04 |
WO2022076622A3 (en) | 2022-07-21 |
US20240150377A1 (en) | 2024-05-09 |
DOP2023000067A (es) | 2023-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20231108A1 (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica | |
PE20231951A1 (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica | |
PE20231185A1 (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica | |
PE20210855A1 (es) | Peptidos macrociclicos contra actinetobacter baumannii | |
CR20240238A (es) | Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico (divisional 2021-0486) | |
PE20211001A1 (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
PE20071137A1 (es) | Derivados de 8-piracin-s-espiropirimidintriona oxaquinolina como agentes antibacterianos | |
PE20010130A1 (es) | Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion | |
CL2009000724A1 (es) | Compuestos derivados de 1,2,3,4-tetrahidro-pirido[3,4-b]indol, moduladores del receptor de histamina, serotonina y dopamina; composicion farmaceutica; kit farmaceutico; y uso para tratar un trastorno cognitivo, psicotico, mediado por neurotransmisores y/o neurologico. | |
PE20180688A1 (es) | Compuestos di-nucleotidos ciclicos como agonistas de sting | |
PE20230309A1 (es) | Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos | |
PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
AR118497A2 (es) | Combinaciones de compuestos activos que comprenden derivados de carboxamida y un agente de control biológico | |
PE20201185A1 (es) | Inhibidores de la oxacina monoacilglicerol lipasa (magl) | |
CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
CO2017008086A2 (es) | Dímeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus métodos de preparación y uso | |
SV2006002110A (es) | Compuestos terapeuticos ref. pc32293a | |
PE20170528A1 (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico | |
PE20090247A1 (es) | Compuestos amino-heterociclicos | |
SV2002000504A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb | |
PE20090511A1 (es) | Imidazopiridinonas | |
TR201905009T4 (tr) | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. | |
GT200900328A (es) | Derivados de bencimidazol | |
CU20210003A7 (es) | Una preparación farmacéutica liposomal de mitoxantrona útil en el tratamiento de linfoma no de hodgkin | |
CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. |